QuinStreet, Inc.

According to the Complaint, QuinStreet made materially false and misleading statements throughout the class period. It alleges that the company displayed reckless disregard in relation to click-through fraud. Sites owned by QuinStreet delivered inflated, false, and/or low-quality traffic for clients. In general, the company’s business practices did not have the aim of delivering to its customers high-potential leads, quality prospects, and useful clicks. As a result, QuinStreet’s claims about the company’s business operations and financial prospects were materially false and misleading throughout the class period. According to the lawsuit, when accurate information about QuinStreet became apparent in the market, investors suffered damages.

-->

Telefonaktiebolaget LM Ericsson

According to the Complaint, the Company issued false and/or misleading statements and/or failed to disclose that: 1) Ericsson prematurely recognized revenues and improperly delayed the recognition of costs related to services contracts; and (2) as a result, Ericsson materially overstated its revenues, margins, and profits during the Class Period. When the truth was revealed to the investing public, shares dropped, causing shareholders harm.

-->

Colony Northstar, Inc.

According to the Complaint, the Company issued false and/or misleading statements and/or failed to disclose that: (1) (1) Colony NorthStar’s Healthcare and Investment Management segments were performing worse than reported; and (2) as a result, Colony NorthStar’s public statements were materially false and misleading at all relevant times. When the truth was revealed to the investing public, shares dropped, causing shareholders harm.

-->

TrueCar, Inc.

According to the Complaint, the Company issued false and/or misleading statements and/or failed to disclose that: (1) the largest source of TrueCar’s revenue, the United States Automobile Association (“USAA”), had been planning significant changes to its website that would have a material adverse effect on the volume of purchases generated by USAA; (2) USAA made significant changes to its website that would have a material adverse effect on the volume of purchases generated by USAA; (3) the changes to USAA’s website maintained by TrueCar caused a material adverse effect on the volume of purchases generated by USAA; and (4) as a result, defendants’ statements about TrueCar’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis. When the truth was revealed to the investing public, shares dropped, causing shareholders harm.

-->

Cancer Genetics, Inc.

According to the Complaint, Cancer Genetics made materially false and misleading statements throughout the class period. It alleges that the company’s internal financial reporting controls were materially weak and deficient. As a result, Cancer Genetics’ financial statements were materially false and misleading throughout the class period and did not accurately reflect the results of business operations and the financial health of the company. According to the lawsuit, when accurate information about Cancer Genetics became apparent in the market, investors suffered damages.

-->

IZEA, Inc.

According to the Complaint, the Company issued false and/or misleading statements and/or failed to disclose that: 1) IZEA was misreporting revenue from the Company’s Content Workflow services as gross amounts billed to marketers instead of on a net transaction basis; (2) the amount IZEA previously reported as gross profit on Content Workflow should be the amount reported as revenue; (3) IZEA lacked adequate internal controls; and (4) as a result, Defendants’ public statements were materially false and misleading at all relevant times. When the truth was revealed to the investing public, shares dropped, causing shareholders harm.

-->

Longfin Corp.

According to the Complaint, the Company issued false and/or misleading statements and/or failed to disclose that: (1) Longfin included several false statements in its SEC filings in connection with its IPO which prompted an SEC investigation, including wrongly representing Defendant Meenavalli’s age, location of Longfin’s principal offices, and listing Sarah Altahawi as an officer when she did not have that position; (2) Longfin acquired Ziddu.com shortly after the IPO to capitalize on the popularly of blockchain companies in order to manipulate the Company’s stock price; (3) Longfin’s acquisition of Ziddu.com prompted an SEC investigation; (4) Longfin knew that it was ineligible to be listed on the Russell 2000 and 3000 indices; and (5) as a result of the foregoing, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the truth was revealed to the investing public, shares dropped, causing shareholders harm.

-->

Overstock.com, Inc.

According to the Complaint, the Company issued false and/or misleading statements and/or failed to disclose that: (1) Overstock.com’s coin offering was highly problematic and potentially illegal; and (2) the company’s Medici business was hemorrhaging money. When the truth was revealed to the investing public, shares dropped, causing shareholders harm.

-->

Solid Biosciences Inc.

According to the Complaint, the Company issued false and/or misleading statements and/or failed to disclose that: (1) Solid Biosciences’ lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) Solid Biosciences misled investors regarding the toxicity of SGT-001; and (3) as a result, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading. When the truth was revealed to the investing public, Solid Biosciences’ share price fell $18.19 per share in the aggregate, causing shareholders harm.

-->

Geron Corporation

According to the Complaint, the Company made false and misleading statements to the market. Geron misled investors and the public about the results of a clinical drug study of imetelstat called IMbark. Based on this fact, the Company’s public statements were false and materially misleading. When the market learned the truth about Geron, investors suffered damages.

-->